{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:30Z","timestamp":1790673930130,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/jhg.2017.91","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T06:48:37Z","timestamp":1504766917000},"page":"1009-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["The pharmacogenomics of valproic acid"],"prefix":"10.1038","volume":"62","author":[{"given":"Miao-Miao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"BFjhg201791_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer, M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53, 26\u201333 (2012).","journal-title":"Epilepsia"},{"key":"BFjhg201791_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","volume":"9","author":"CU Johannessen","year":"2003","unstructured":"Johannessen, C. U. & Johannessen, S. I. Valproate: past, present, and future. CNS Drug Rev. 9, 199\u2013216 (2003).","journal-title":"CNS Drug Rev."},{"key":"BFjhg201791_CR3","doi-asserted-by":"publisher","first-page":"pii:479364","DOI":"10.1155\/2010\/479364","volume":"2010","author":"S Chateauvieux","year":"2010","unstructured":"Chateauvieux, S., Morceau, F., Dicato, M. & Diederich, M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010, pii:479364 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"BFjhg201791_CR4","doi-asserted-by":"publisher","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A. & Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734\u201336741 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFjhg201791_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yebeh.2005.04.010","volume":"7","author":"TN Ferraro","year":"2005","unstructured":"Ferraro, T. N. & Buono, R. J. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav. 7, 18\u201336 (2005).","journal-title":"Epilepsy Behav."},{"key":"BFjhg201791_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik, Y., Thorn, C. F., Lamba, J. K., Leeder, J. S., Song, W., Birnbaum, A. K. et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 23, 236\u2013241 (2013).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201791_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00007691-198903000-00002","volume":"11","author":"RG Dickinson","year":"1989","unstructured":"Dickinson, R. G., Hooper, W. D., Dunstan, P. R. & Eadie, M. J. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther. Drug Monit. 11, 127\u2013133 (1989).","journal-title":"Ther. Drug Monit."},{"key":"BFjhg201791_CR8","first-page":"25","volume":"37","author":"CL DeVane","year":"2003","unstructured":"DeVane, C. L. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull. 37, 25\u201342 (2003).","journal-title":"Psychopharmacol. Bull."},{"key":"BFjhg201791_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","volume":"112","author":"L Tan","year":"2010","unstructured":"Tan, L., Yu, J., Sun, Y., Ou, J., Song, J. & Yu, Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg. 112, 320\u2013323 (2010).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"BFjhg201791_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TKL Kiang","year":"2006","unstructured":"Kiang, T. K. L., Ho, P. C., Anari, M. R., Tong, V., Abbott, F. S. & Chang, T. K. H. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol. Sci. 94, 261\u2013271 (2006).","journal-title":"Toxicol. Sci."},{"key":"BFjhg201791_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","volume":"3","author":"PC Ho","year":"2003","unstructured":"Ho, P. C., Abbott, F. S., Zanger, U. M. & Chang, T. K. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 3, 335\u2013342 (2003).","journal-title":"Pharmacogenomics J."},{"key":"BFjhg201791_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/epi.13011","volume":"56","author":"T Budi","year":"2015","unstructured":"Budi, T., Toth, K., Nagy, A., Szever, Z., Kiss, A., Temesvari, M. et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 56, 849\u2013855 (2015).","journal-title":"Epilepsia"},{"key":"BFjhg201791_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/15376516.2010.497977","volume":"20","author":"N Amini-Shirazi","year":"2010","unstructured":"Amini-Shirazi, N., Ghahremani, M. H., Ahmadkhaniha, R., Mandegary, A., Dadgar, A., Abdollahi, M. et al. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol. Mech. Methods 20, 452\u2013457 (2010).","journal-title":"Toxicol. Mech. Methods"},{"key":"BFjhg201791_CR14","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","volume":"15","author":"MT Voso","year":"2009","unstructured":"Voso, M. T., Santini, V., Finelli, C., Musto, P., Pogliani, E., Angelucci, E. et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin. Cancer. Res. 15, 5002\u20135007 (2009).","journal-title":"Clin. Cancer. Res."},{"key":"BFjhg201791_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2217\/pgs.12.78","volume":"13","author":"D Chatzistefanidis","year":"2012","unstructured":"Chatzistefanidis, D., Georgiou, I., Kyritsis, A. P. & Markoula, S. Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics 13, 1055\u20131071 (2012).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201791_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejphar.2013.09.024","volume":"721","author":"L Zhang","year":"2013","unstructured":"Zhang, L., Chu, X., Wang, H., Xie, H., Guo, C., Cao, L. et al. Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver. Eur. J. Pharmacol. 721, 277\u2013285 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"BFjhg201791_CR17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1124\/jpet.104.081968","volume":"313","author":"S Krishnaswamy","year":"2005","unstructured":"Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von, Moltke, L. L., Greenblatt, D. J. et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther. 313, 1340\u20131346 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFjhg201791_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/pgs.11.64","volume":"12","author":"CC Hung","year":"2011","unstructured":"Hung, C. C., Ho, J. L., Chang, W. L., Tai, J. J., Hsieh, T. J., Hsieh, Y. W. et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12, 1107\u20131117 (2011).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201791_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","volume":"27","author":"Y Guo","year":"2012","unstructured":"Guo, Y., Hu, C., He, X., Qiu, F. & Zhao, L. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab. Pharmacokinet. 27, 536\u2013542 (2012).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"BFjhg201791_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","volume":"36","author":"K Inoue","year":"2014","unstructured":"Inoue, K., Suzuki, E., Yazawa, R., Yamamoto, Y., Takahashi, Y., Imai, K. et al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther. Drug Monit. 36, 406\u2013409 (2014).","journal-title":"Ther. Drug Monit."},{"key":"BFjhg201791_CR21","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","volume":"68","author":"XM Chu","year":"2012","unstructured":"Chu, X. M., Zhang, L. F., Wang, G. J., Zhang, S. N., Zhou, J. H. & Hao, H. P. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur. J. Clin. Pharmacol. 68, 1395\u20131401 (2012).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BFjhg201791_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","volume":"114","author":"YX Sun","year":"2015","unstructured":"Sun, Y. X., Zhuo, W. Y., Lin, H., Peng, Z. K., Wang, H. M., Huang, H. W. et al. The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res. 114, 78\u201380 (2015).","journal-title":"Epilepsy Res."},{"key":"BFjhg201791_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","volume":"38","author":"Q Wang","year":"2016","unstructured":"Wang, Q., Zhao, L., Liang, M., Dong, Y., Yun, W., Qiu, F. et al. Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine. Ther. Drug Monit. 38, 343\u2013349 (2016).","journal-title":"Ther. Drug Monit."},{"key":"BFjhg201791_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","volume":"70","author":"C Fattore","year":"2006","unstructured":"Fattore, C., Messina, S., Battino, D., Croci, D., Mamoli, D. & Perucca, E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res. 70, 153\u2013160 (2006).","journal-title":"Epilepsy Res."},{"key":"BFjhg201791_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1734-1140(12)70900-3","volume":"64","author":"KM Stepien","year":"2012","unstructured":"Stepien, K. M., Tomaszewski, M., Tomaszewska, J. & Czuczwar, S. J. The multidrug trans- porter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol. Rep. 64, 1011\u20131019 (2012).","journal-title":"Pharmacol. Rep."},{"key":"BFjhg201791_CR26","first-page":"S32","volume":"17","author":"R Kumari","year":"2011","unstructured":"Kumari, R., Lakhan, R., Garg, R. K., Kalita, J., Misra, U. K. & Mittal, B. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian. J. Hum. Genet. 17, S32\u2013S40 (2011).","journal-title":"J. Hum. Genet."},{"key":"BFjhg201791_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00019052-200304000-00013","volume":"16","author":"SM Sisodiya","year":"2003","unstructured":"Sisodiya, S. M. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16, 197\u2013201 (2003).","journal-title":"Curr. Opin. Neurol."},{"key":"BFjhg201791_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","volume":"18","author":"CC Hung","year":"2008","unstructured":"Hung, C. C., Chen, C. C., Lin, C. J. & Liou, H. H. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet. Genomics 18, 390\u2013402 (2008).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg201791_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G. et al. Definition of drug resistantepilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commissionon Therapeutic Strategies. Epilepsia 51, 1069\u20131077 (2010).","journal-title":"Epilepsia"},{"key":"BFjhg201791_CR30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMoa021986","volume":"348","author":"A Siddiqui","year":"2003","unstructured":"Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B. et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442\u20131448 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFjhg201791_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eplepsyres.2015.05.015","volume":"115","author":"L Yu","year":"2015","unstructured":"Yu, L., Liao, W., Yi, Y. & Qiu, G. ABCB1 G2677T\/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians. Epilepsy Res. 115, 100\u2013108 (2015).","journal-title":"Epilepsy Res."},{"key":"BFjhg201791_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.seizure.2011.01.008","volume":"20","author":"BS Haerian","year":"2011","unstructured":"Haerian, B. S., Lim, K. S., Mohamed, E. H., Tan, H. J., Tan, C. T., Raymond, A. A. et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 20, 387\u2013394 (2011).","journal-title":"Seizure"},{"key":"BFjhg201791_CR33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1684\/epd.2011.0419","volume":"13","author":"BS Haerian","year":"2011","unstructured":"Haerian, B. S., Lim, K. S., Tan, H. J., Mohamed, E. H., Tan, C. T., Raymond, A. A. et al. Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord. 13, 65\u201375 (2011).","journal-title":"Epileptic Disord."},{"key":"BFjhg201791_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11033-007-9206-z","volume":"36","author":"G Turgut","year":"2009","unstructured":"Turgut, G., Kurt, E., Sengul, C., Alatas, G., Kursunluoglu, R., Oral, T. et al. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol. Biol. Rep. 36, 495\u2013499 (2009).","journal-title":"Mol. Biol. Rep."},{"key":"BFjhg201791_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5808\/GI.2013.11.4.254","volume":"11","author":"JH Yi","year":"2013","unstructured":"Yi, J. H., Cho, Y., Kim, W., Lee, M. G. & Lee, J. H. Genetic variations of ABCC2 gene associated with adverse drug reactions to valproic acid in Korean epileptic patients. Genomics Inform. 11, 254\u2013262 (2013).","journal-title":"Genomics Inform."},{"key":"BFjhg201791_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0278-5846(82)80172-3","volume":"6","author":"E Mesdjian","year":"1982","unstructured":"Mesdjian, E., Ciesielski, L., Valli, M., Bruguerolle, B., Jadot, G., Bouyard, P. et al. Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 6, 223\u2013233 (1982).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"BFjhg201791_CR37","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2217\/pgs-2016-0093","volume":"17","author":"X Li","year":"2016","unstructured":"Li, X., Zhang, J., Wu, X., Yan, H., Zhang, Y., He, R. H. et al. Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics 17, 2007\u20132014 (2016).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201791_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1570-0232(03)00276-9","volume":"792","author":"T Shinka","year":"2003","unstructured":"Shinka, T., Ohfu, M., Hirose, S. & Kuhara, T. Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 792, 99\u2013106 (2003).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"BFjhg201791_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1528-1157.1986.tb03525.x","volume":"27","author":"AM VanDongen","year":"1986","unstructured":"VanDongen, A. M., VanErp, M. G. & Voskuyl, R. A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 27, 177\u2013182 (1986).","journal-title":"Epilepsia"},{"key":"BFjhg201791_CR40","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/pgs.13.104","volume":"14","author":"BS Haerian","year":"2013","unstructured":"Haerian, B. S., Baum, L., Kwan, P., Tan, H. J., Raymond, A. A. & Mohamed, Z. SCN1A,SCN2A andSCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14, 1153\u20131166 (2013).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201791_CR41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2217\/pgs.12.127","volume":"13","author":"BS Haerian","year":"2012","unstructured":"Haerian, B. S., Baum, L., Tan, H. J., Kwan, P., Raymond, A. A., Saruwatari, J. et al. SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 13, 1477\u20131485 (2012).","journal-title":"Pharmacogenomics"},{"key":"BFjhg201791_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.seizure.2015.05.013","volume":"30","author":"N Lv","year":"2015","unstructured":"Lv, N., Qu, J., Long, H., Zhou, L., Cao, Y., Long, L. et al. Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population. Seizure 30, 64\u201369 (2015).","journal-title":"Seizure"},{"key":"BFjhg201791_CR43","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969\u20136978 (2001).","journal-title":"EMBO J."},{"key":"BFjhg201791_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Chavez-Blanco","year":"2006","unstructured":"Chavez-Blanco, A., Perez-Plasencia, C., Perez-Cardenas, E., Carrasco-Legleu, C., Rangel-Lopez, E., Segura-Pacheco, B. et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 6, 2 (2006).","journal-title":"Cancer Cell Int."},{"key":"BFjhg201791_CR45","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","volume":"19","author":"CA Bradbury","year":"2005","unstructured":"Bradbury, C. A., Khanim, F. L., Hayden, R., Bunce, C. M., White, D. A., Drayson, M. T. et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19, 1751\u20131759 (2005).","journal-title":"Leukemia"},{"key":"BFjhg201791_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/stem.1544","volume":"32","author":"F Paino","year":"2014","unstructured":"Paino, F., La, Noce, M., Tirino, V., Naddeo, P., Desiderio, V., Pirozzi, G. et al. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells 32, 279\u2013289 (2014).","journal-title":"Stem Cells"},{"key":"BFjhg201791_CR47","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau, R. M. & Neuman, M. G. Adverse drug reactions induced by valproic acid. Clin. Biochem. 46, 1323\u20131338 (2013).","journal-title":"Clin. Biochem."},{"key":"BFjhg201791_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/toxsci\/kfi185","volume":"86","author":"V Tong","year":"2005","unstructured":"Tong, V. Valproic acid II: effects on oxidative stress, mitochondria membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 86, 436\u2013443 (2005).","journal-title":"Toxicol. Sci."},{"key":"BFjhg201791_CR49","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tiv.2012.01.020","volume":"26","author":"J Pourahmad","year":"2012","unstructured":"Pourahmad, J., Eskandari, M. R., Kaghazi, A., Shaki, F., Shahraki, J. & Fard, J. K. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol. In Vitro 26, 545\u2013551 (2012).","journal-title":"Toxicol. In Vitro"},{"key":"BFjhg201791_CR50","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1128\/AAC.00854-16","volume":"60","author":"HM Hassan","year":"2016","unstructured":"Hassan, H. M., Guo, H., Yousef, B. A., Guerram, M., Hamdi, A. M., Zhang, L. et al. Role of inflammatory and oxidative stress, cytochrome P450 2E1, and bile acid disturbance in rat liver injury induced by isoniazid and lipopolysaccharide cotreatment. Antimicrob. Agents Chemother. 60, 5285\u20135293 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFjhg201791_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/humu.20813","volume":"30","author":"S Mitchell","year":"2009","unstructured":"Mitchell, S., Ellingson, C., Coyne, T., Hall, L., Neill, M., Christian, N. et al. Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases. Hum. Mutat. 30, 56\u201360 (2009).","journal-title":"Hum. Mutat."},{"key":"BFjhg201791_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","volume":"55","author":"CC Aires","year":"2011","unstructured":"Aires, C. C., van, Cruchten, A., Ijlst, L., de, Almeida, I. T., Duran, M., Wanders, R. J. et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J. Hepatol. 55, 426\u2013434 (2011).","journal-title":"J. Hepatol."},{"key":"BFjhg201791_CR53","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajpath.2010.10.023","volume":"178","author":"H Liu","year":"2011","unstructured":"Liu, H., Dong, H., Robertson, K. & Liu, C. DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am. J. Pathol. 178, 652\u2013661 (2011).","journal-title":"Am. J. Pathol."},{"key":"BFjhg201791_CR54","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","volume":"52","author":"M Yagi","year":"2010","unstructured":"Yagi, M., Nakamura, T., Okizuka, Y., Oyazato, Y., Kawasaki, Y., Tsuneishi, S. et al. Effect of CPS1 4217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr. Int. 52, 744\u2013748 (2010).","journal-title":"Pediatr. Int."},{"key":"BFjhg201791_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/261497","volume":"2013","author":"PK Janicki","year":"2013","unstructured":"Janicki, P. K., Bezinover, D., Postula, M., Thompson, R. S., Acharya, J., Acharya, V. et al. Increased occurrence of valproic acid-induced hyperammonemia in carriers of T1405N polymorphism in carbamoyl phosphate synthetase 1 gene. ISRN Neurol 2013, 1\u20134 (2013).","journal-title":"ISRN Neurol"},{"key":"BFjhg201791_CR56","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eplepsyres.2014.04.008","volume":"108","author":"K Inoue","year":"2014","unstructured":"Inoue, K., Suzuki, E., Takahashi, T., Yamamoto, Y., Yazawa, R., Takahashi, Y. et al. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. Epilepsy Res. 108, 1046\u20131051 (2014).","journal-title":"Epilepsy Res."},{"key":"BFjhg201791_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.seizure.2015.10.015","volume":"33","author":"K Inoue","year":"2015","unstructured":"Inoue, K., Takahashi, T., Yamamoto, Y., Suzuki, E., Takahashi, K., Imai, K. et al. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. Seizure 33, 76\u201380 (2015).","journal-title":"Seizure"},{"key":"BFjhg201791_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1023\/A:1021918104127","volume":"17","author":"A Verrotti","year":"2002","unstructured":"Verrotti, A., Trotta, D., Morgese, G. & Chiarelli, F. Valproate-induced hyperammonemic encephalopathy. Metab. Brain. Dis. 17, 367\u2013373 (2002).","journal-title":"Metab. Brain. Dis."},{"key":"BFjhg201791_CR59","doi-asserted-by":"publisher","first-page":"R244","DOI":"10.1093\/hmg\/ddl233","volume":"15","author":"G Hudson","year":"2006","unstructured":"Hudson, G. Mitochondria DNA polymerase-\u03b3 and human disease. Hum. Mol. Genet. 15, R244\u2013R252 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFjhg201791_CR60","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/hep.23891","volume":"52","author":"JD Stewart","year":"2010","unstructured":"Stewart, J. D., Horvath, R., Baruffini, E., Ferrero, L., Bulst, S., Watkins, P. B. et al. Polymerase \u03b3 Gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52, 1791\u20131796 (2010).","journal-title":"Hepatology"},{"key":"BFjhg201791_CR61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.seizure.2010.01.002","volume":"19","author":"RP Saneto","year":"2010","unstructured":"Saneto, R. P., Lee, I. C., Koenig, M. K., Bao, X., Weng, S. W., Naviaux, R. K. et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 19, 140\u2013146 (2010).","journal-title":"Seizure"},{"key":"BFjhg201791_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2014.03.006","volume":"112","author":"KS Sitarz","year":"2014","unstructured":"Sitarz, K. S., Elliott, H. R., Karaman, B. S., Relton, C., Chinnery, P. F. & Horvath, R. Valproic acid triggers increased mitochondria biogenesis in POLG-deficient fibroblasts. Mol. Genet. Metab. 112, 57\u201363 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg201791_CR63","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/lt.23965","volume":"20","author":"J Hynynen","year":"2014","unstructured":"Hynynen, J., Komulainen, T., Tukiainen, E., Nordin, A., Arola, J., Kalviainen, R. et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl. 20, 1402\u20131412 (2014).","journal-title":"Liver Transpl."},{"key":"BFjhg201791_CR64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2007.11.035","volume":"389","author":"Y Fukushima","year":"2008","unstructured":"Fukushima, Y., Seo, T., Hashimoto, N., Higa, Y., Ishitsu, T. & Nakagawa, K. Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum \u03b3-glutamyltransferase in valproic acid-treated patients. Clin. Chim. Acta 389, 98\u2013102 (2008).","journal-title":"Clin. Chim. Acta"},{"key":"BFjhg201791_CR65","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eplepsyres.2011.10.033","volume":"99","author":"J Saruwatari","year":"2012","unstructured":"Saruwatari, J., Deguchi, M., Yoshimori, Y., Noai, M., Yoshida, S., Ogusu, N. et al. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res. 99, 183\u2013186 (2012).","journal-title":"Epilepsy Res."},{"key":"BFjhg201791_CR66","first-page":"993","volume":"54","author":"CL Hsieh","year":"2013","unstructured":"Hsieh, C. L., Chen, K. C., Ding, C. Y., Tsai, W. J., Wu, J. F. & Peng, C. C. Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model. Rom. J. Morphol. Embryol. 54, 993\u20131004 (2013).","journal-title":"Rom. J. Morphol. Embryol."},{"key":"BFjhg201791_CR67","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.seizure.2013.05.003","volume":"22","author":"K Phabphal","year":"2013","unstructured":"Phabphal, K. & Geater, A. The association between BsmI polymorphism and risk factors for atherosclerosis in patients with epilepsy taking valproate. Seizure 22, 692\u2013697 (2013).","journal-title":"Seizure"},{"key":"BFjhg201791_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.psychres.2008.05.010","volume":"168","author":"B Kim","year":"2009","unstructured":"Kim, B., Kim, C. Y., Lee, M. J. & Joo, Y. H. Preliminary evidence on the association between XBP1-116C\/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiat. Res. 168, 209\u2013212 (2009).","journal-title":"Psychiat. Res."},{"key":"BFjhg201791_CR69","first-page":"1","volume":"18","author":"H Li","year":"2015","unstructured":"Li, H., Wang, X., Zhou, Y., Ni, G., Su, Q., Chen, Z. et al. Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. Int. J. Neuropsychopharmacol 18, 1\u20137 (2015).","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"BFjhg201791_CR70","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1007\/s11033-014-3330-3","volume":"41","author":"Y Dodurga","year":"2014","unstructured":"Dodurga, Y., Gundogdu, G., Tekin, V., Koc, T., Satiroglu-Tufan, N. L., Bagci, G. et al. Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4\/URGCP and CCND1 gene expression. Mol. Biol. Rep. 41, 4595\u20134599 (2014).","journal-title":"Mol. Biol. Rep."},{"key":"BFjhg201791_CR71","first-page":"348","volume":"28","author":"D Schmidt","year":"2014","unstructured":"Schmidt, D. & Schachter, S. C. Drug treatment of epilepsy in adults. BMJ 28, 348 g254 (2014).","journal-title":"BMJ"},{"key":"BFjhg201791_CR72","doi-asserted-by":"publisher","first-page":"e0141266","DOI":"10.1371\/journal.pone.0141266","volume":"10","author":"H Nakashima","year":"2015","unstructured":"Nakashima, H., Oniki, K., Nishimura, M., Ogusu, N., Shimomasuda, M. & Ono, T. Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE 10, e0141266 (2015).","journal-title":"PLoS ONE"}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhg201791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhg201791","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/jhg.2017.91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/jhg201791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T22:08:29Z","timestamp":1640988509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg201791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFjhg201791"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2017.91","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]},"assertion":[{"value":"6 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}